-
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Groen, K., Smits, F., Nasserinejad, K., Levin, M-D., Regelink, J. C., Timmers, G-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Jul 2024, In: HemaSphere. 8, 7, e85.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Treatment sequences and drug costs from diagnosis to death in multiple myeloma
Seefat, M. R., Cucchi, D. G. J., Groen, K., Donker, M. L., van der Hem, K. G., Westerman, M., Gerrits, A. M., Beeker, A., van de Donk, N. W. C. J., Blommestein, H. M. & Zweegman, S., 11 Oct 2023, (E-pub ahead of print) In: European journal of haematology.Research output: Contribution to journal › Article › Academic › peer-review
-
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Groen, K., Schjesvold, F. H., van der Holt, B., Levin, M-D., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., Axelsson, P., Hieu Do, T., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C. H., Mellqvist, U-H., van de Donk, N. W. C. J., & 5 others, 30 Sept 2023, In: HemaSphere. 7, 9, p. E940Research output: Contribution to journal › Letter › Academic › peer-review
- All publications
